Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
181 hedge funds and large institutions have $2.9B invested in Akero Therapeutics in 2023 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 79 increasing their positions, 39 reducing their positions, and 12 closing their positions.
217% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 12
103% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 39
15% more funds holding
Funds holding: 157 → 181 (+24)
10% more capital invested
Capital invested by funds: $2.63B → $2.9B (+$271M)
0.84% more ownership
Funds ownership: 101.88% → 102.72% (+0.84%)
7% less call options, than puts
Call options by funds: $140M | Put options by funds: $151M
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$54.1M |
| 2 |
BlackRock
New York
|
+$30.6M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$25.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$24.2M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ST
Skorpios Trust
Limassol,
Cyprus
|
-$75.7M |
| 2 |
CC
Commodore Capital
New York
|
-$51.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$51.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$30.8M |
| 5 |
PA
Perceptive Advisors
New York
|
-$15M |
AKRO Hedge Fund Activity: Q3 2023 in Review
181 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2023, worth a combined $2.9B — up 10% from $2.63B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AKRO positions and 12 closed out — a net gain of 26 holders — while 79 added to existing stakes and 39 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $54.1M. The largest seller was Skorpios Trust, exiting entirely with an estimated $75.7M sold.
- 181 institutional investors held Akero Therapeutics (AKRO) as of Q3 2023, up from 157 in Q2 2023.
- Funds reported $2.9B of Akero Therapeutics stock for Q3 2023, up 10% quarter-over-quarter.
- 38 funds opened new Akero Therapeutics positions in Q3 2023 and 12 closed out, a net change of +26 holders.
- The largest Akero Therapeutics buyer in Q3 2023 was AllianceBernstein, an estimated $54.1M added.
- The largest Akero Therapeutics seller in Q3 2023 was Skorpios Trust, an estimated $75.7M sold.
Based on aggregated 13F filings for Q3 2023.